Rigel Pharmaceuticals (RIGL)

Executive Summary

Rigel Pharmaceuticals is a biotechnology company focused on developing therapies for hematologic disorders and cancer. Its approved products include Tavalisse (fostamatinib) for immune thrombocytopenic purpura (ITP) and Rezlidhia (olutasidenib) for IDH1-mutant acute myeloid leukemia (AML). The company's pipeline targets warm antibody autoimmune hemolytic anemia (AIHA), acute respiratory distress syndrome (ARDS), IgA nephropathy, and low-risk myelodysplastic syndromes (MDS), among others. Key near-term catalysts include Phase 3 results for fostamatinib in warm AIHA (top-line data expected in late 2026), Phase 2 data for fostamatinib in ARDS (interim readout in 2027), and progress with R289 in MDS (Phase 1/2 data in H2 2026). Revenue growth from existing products and pipeline advancement support a moderate conviction, but execution risk and competitive pressures remain.

Upcoming Catalysts (preview)

• Q4 2026Fostamatinib Phase 3 top-line data in warm AIHA55% success
• Q4 2026R289 Phase 1/2 initial efficacy data in low-risk MDS40% success
• Q2 2027Fostamatinib Phase 2 interim data in ARDS50% success